1416319-50-0

Basic information

• Product Name: 3-(4-methoxyphenyl)-2-phenylimidazo[1,2-a]pyridine
• Synonyms: 3-(4-methoxyphenyl)-2-phenylimidazo[1,2-a]pyridine
• CAS NO: 1416319-50-0
• Molecular Weight: 300.36
• Mol File: 1416319-50-0.mol

Chemical Properties

• CAS DataBase Reference: 3-(4-methoxyphenyl)-2-phenylimidazo[1,2-a]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-methoxyphenyl)-2-phenylimidazo[1,2-a]pyridine(1416319-50-0)
• EPA Substance Registry System: 3-(4-methoxyphenyl)-2-phenylimidazo[1,2-a]pyridine(1416319-50-0)

Safety Data

• Hazardous Substances Data: 1416319-50-0(Hazardous Substances Data)

Upstream product

• 4044-95-5 2-Phenyl-3-bromoimidazo<1,2-a>pyridine 
• 5720-07-0 4-methoxyphenylboronic acid 
• 1373338-15-8 2-iodoimidazo[1,2-a]pyridine 
• 3999-05-1 2-chloroimidazo[1,2-a]pyridine 
• 70-11-1 α-bromoacetophenone 
• 504-29-0 2-aminopyridine 
• 1021019-74-8 imidazo[1,2-a]pyridin-2-yl trifluoromethanesulfonate 
• 104-92-7 1-bromo-4-methoxy-benzene 
• 4105-21-9 2-phenylimidazo[1,2-a]pyridine 

Relevant articles and documents

Regiocontrolled functionalization of 2,3-dihalogenoimidazo[1,2-a]pyridines by Suzuki-Miyaura and Sonogashira cross-coupling reactions

An efficient method for regiocontrolled functionalization of 2,3-dihalogenoimidazo[1,2-a]pyridine was developed. This sequence allowed the selective introduction of aryl, heteroaryl, alkyl and alkynyl substituents at both 2- and 3-positions, by using Suzu

Straightforward synthesis of various 2,3-diarylimidazo[1,2-a]pyridines in peg400 medium through one-pot condensation and C-H arylation

PEG400 is described herein as a suitable medium for the condensation of various 2-amino pyridines with α-bromo ketones. 2-Arylimidazo[1,2-a]pyridines were synthetized in a short time through microwave irradiation in moderate to excellent yields

Synthesis and biological evaluation of 2,3-diarylimidazo[1,2-a]pyridines as antileishmanial agents

A novel series of 2,3-diarylimidazo[1,2-a]pyridines was synthesized and evaluated for their antileishmanial activities. Four derivatives exhibited good activity against the promastigote and intracellular amastigote stages of Leishmania major, coupled with a low cytotoxicity against the HeLa human cell line. The impact of compound lipophilicity on antiparasitic activities was investigated by Log D comparison. Although LmCK1 could be the parasitic target for three compounds (13, 18, 21), the inhibition of another target is under study to explain the antileishmanial effect of the most promising compounds.